Foghorn Therapeutics Inc. announced its financial and corporate update for the second quarter ended June 30, 2025, revealing a strengthened financial outlook. The company reported $198.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025. This capital position is now expected to provide a cash runway into 2028, an extension from previous projections.
The FHD-909 Phase 1 dose escalation trial, part of the strategic collaboration with Eli Lilly, is enrolling well and remains on track. Preclinical data showing synergistic benefit of FHD-909 in combination with pembrolizumab and KRAS inhibitors further reinforces its potential in difficult-to-treat non-small cell lung cancer (NSCLC).
Foghorn's wholly-owned selective degrader programs are also advancing, with the Selective CBP degrader on track for IND-enabling studies and targeting an IND in 2026. Program updates for both the Selective EP300 degrader and Selective ARID1B degrader are anticipated in the fourth quarter of 2025, indicating continued momentum across the pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.